Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115110 | 0.89 | DRD2 (0.47) | DRD2DRD4PRCPKDM1AMAPT | |
| SCHEMBL5506511 | 0.87 | DRD2 (0.46) | DRD2DRD4GSK3BPRCPKDM1A | |
| SCHEMBL5121453 | 0.83 | DRD2 (0.49) | DRD2DRD4GSK3BCYP11B1CYP11B2 | |
| SCHEMBL5112936 | 0.82 | DRD2 (0.40) | DRD2DRD4GSK3BCYP11B1CYP11B2 | |
| SCHEMBL28770473 | 0.80 | DRD2 (0.39) | DRD2CYP11B1CYP11B2 | |
| SCHEMBL5120594 | 0.80 | CYP11B2 (0.42) | DRD2CYP11B1CYP11B2KDM1A | |
| SCHEMBL5115279 | 0.80 | ACHE (0.44) | DRD2KDM1AMAPTACHEOPRM1 | |
| SCHEMBL3167913 | 0.76 | CYP11B2 (0.41) | DRD2CYP11B1CYP11B2 | |
| SCHEMBL5504474 | 0.76 | DRD2 (0.43) | DRD2DRD4PRCPKDM1AMAPT | |
| SCHEMBL3178366 | 0.74 | OPRD1 (0.38) | DRD2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | DRD2 205/4885DRD4 495/4885GSK3B 594/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | DRD2 205/4885DRD4 495/4885GSK3B 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.